Dubai Telegraph - Vaccine supply outstrips demand, access inequity remains

EUR -
AED 3.826681
AFN 70.961758
ALL 98.138602
AMD 405.652886
ANG 1.877182
AOA 951.190259
ARS 1045.840133
AUD 1.602814
AWG 1.877897
AZN 1.775245
BAM 1.955573
BBD 2.102956
BDT 124.465544
BGN 1.955633
BHD 0.392554
BIF 3076.642669
BMD 1.041829
BND 1.403837
BOB 7.197164
BRL 6.043693
BSD 1.041579
BTN 87.914489
BWP 14.229347
BYN 3.408604
BYR 20419.848375
BZD 2.099456
CAD 1.456529
CDF 2991.091432
CHF 0.930957
CLF 0.036923
CLP 1018.83097
CNY 7.54601
CNH 7.562783
COP 4573.368835
CRC 530.538382
CUC 1.041829
CUP 27.608468
CVE 110.252195
CZK 25.343745
DJF 185.478458
DKK 7.457729
DOP 62.772709
DZD 139.891631
EGP 51.726992
ERN 15.627435
ETB 127.508391
FJD 2.371151
FKP 0.822333
GBP 0.831435
GEL 2.855018
GGP 0.822333
GHS 16.456089
GIP 0.822333
GMD 73.970229
GNF 8977.957272
GTQ 8.040066
GYD 217.904692
HKD 8.109446
HNL 26.320943
HRK 7.431636
HTG 136.72412
HUF 411.522823
IDR 16610.452733
ILS 3.863061
IMP 0.822333
INR 87.968134
IQD 1364.44153
IRR 43834.955489
ISK 145.523076
JEP 0.822333
JMD 165.930728
JOD 0.738765
JPY 161.242873
KES 134.884334
KGS 90.122166
KHR 4193.512952
KMF 492.268155
KPW 937.645704
KRW 1463.259646
KWD 0.320727
KYD 0.867999
KZT 520.059599
LAK 22878.342838
LBP 93271.167197
LKR 303.144792
LRD 187.998165
LSL 18.795317
LTL 3.076251
LVL 0.630192
LYD 5.086409
MAD 10.478083
MDL 18.997794
MGA 4861.435378
MKD 61.522855
MMK 3383.819949
MNT 3540.134882
MOP 8.35093
MRU 41.443187
MUR 48.810083
MVR 16.10707
MWK 1806.090235
MXN 21.281613
MYR 4.654932
MZN 66.583684
NAD 18.795317
NGN 1767.675143
NIO 38.325549
NOK 11.531328
NPR 140.663663
NZD 1.78585
OMR 0.401144
PAB 1.041579
PEN 3.949541
PGK 4.193513
PHP 61.404399
PKR 289.239507
PLN 4.337676
PYG 8131.055634
QAR 3.798559
RON 4.978071
RSD 117.038068
RUB 108.671879
RWF 1421.834864
SAR 3.911473
SBD 8.734231
SCR 14.266343
SDG 626.663972
SEK 11.501974
SGD 1.402931
SHP 0.822333
SLE 23.68116
SLL 21846.638123
SOS 595.230868
SRD 36.978718
STD 21563.75683
SVC 9.113941
SYP 2617.626467
SZL 18.788818
THB 35.922648
TJS 11.092512
TMT 3.646401
TND 3.309016
TOP 2.440072
TRY 36.018972
TTD 7.074178
TWD 33.946439
TZS 2770.578216
UAH 43.089995
UGX 3848.553017
USD 1.041829
UYU 44.294855
UZS 13362.448044
VES 48.506662
VND 26482.251319
VUV 123.688032
WST 2.90836
XAF 655.880824
XAG 0.033274
XAU 0.000384
XCD 2.815595
XDR 0.792308
XOF 655.880824
XPF 119.331742
YER 260.379151
ZAR 18.862746
ZMK 9377.71492
ZMW 28.772658
ZWL 335.468513
  • SCS

    0.2300

    13.27

    +1.73%

  • RIO

    -0.2200

    62.35

    -0.35%

  • CMSC

    0.0320

    24.672

    +0.13%

  • RELX

    0.9900

    46.75

    +2.12%

  • GSK

    0.2600

    33.96

    +0.77%

  • CMSD

    0.0150

    24.46

    +0.06%

  • AZN

    1.3700

    65.63

    +2.09%

  • NGG

    1.0296

    63.11

    +1.63%

  • RYCEF

    -0.0100

    6.79

    -0.15%

  • BCE

    0.0900

    26.77

    +0.34%

  • BTI

    0.4000

    37.38

    +1.07%

  • VOD

    0.1323

    8.73

    +1.52%

  • BCC

    3.4200

    143.78

    +2.38%

  • BP

    0.2000

    29.72

    +0.67%

  • RBGPF

    59.2400

    59.24

    +100%

  • JRI

    -0.0200

    13.21

    -0.15%

Vaccine supply outstrips demand, access inequity remains
Vaccine supply outstrips demand, access inequity remains

Vaccine supply outstrips demand, access inequity remains

After two years of racing to vaccinate the world against Covid-19, the number of available doses now surpasses demand in many areas.

Text size:

Yet a yawning gap remains in vaccination rates between the richest and poorest countries.

On Friday, Gavi, which co-leads the Covax global distribution scheme, is holding a summit calling for more funds to address the issue of inequality in vaccine access.

- Huge production -

More than 13 billion doses have been produced since the pandemic, 11 billion of which have been administered, according to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

Science research group Airfinity expect nine billion more doses to be produced this year. Pfizer alone plans to make four billion doses.

Yet demand could fall to six billion doses this year, IFPMA's director general Thomas Cueni said.

"Since mid-2021, global vaccine production has exceeded global vaccine demand and this gap has continuously risen," Cueni told AFP.

By next year, production could exceed demand by 1.3 to 3.1 billion doses, he added.

Many richer nations are now approaching oversupply. European Union and G7 countries had a surplus of 497 million doses at the end of last month.

There are fears that doses could go to waste. Covid vaccines have a relatively short shelf-life -- AstraZeneca and Novavax's jabs have a six-month expiry date.

Airfinity says 241 million doses have passed their sell-by date so far during the pandemic.

- Billions unvaccinated -

Nevertheless, billions of people remain unvaccinated around the world, most of them in developing nations.

Covax, an international public-private partnership co-led by WHO and Gavi, has delivered 1.4 billion doses to 145 countries -- far short of the planned two billion doses by end-2021.

World Health Organization chief Tedros Adhanom Ghebreyesus has warned that inequality in vaccine access could lead to the emergence of new, possibly more contagious variants.

The WHO wants 70 percent of every country's population vaccinated by July.

But records are uneven.

Nearly 80 percent of France's population, for example, has received two doses. But only 15 percent of the population on the continent of Africa is fully vaccinated, according to Oxford University data.

An average of 42 percent of the population of 92 low- and middle-income countries participating in Covax have had one dose.

"Vaccine inequity is the biggest moral failure of our times and people and countries are paying the price," UN Secretary-General Antonio Guterres said earlier this year.

Covax says it now has enough doses to vaccinate around 45 percent of the population in the 92 countries receiving donations. But 25 of those countries lack the infrastructure for an effective immunisation campaign.

Making matters worse, many developing countries are being donated doses too close to their expiry date.

UNICEF's supply division director Etleva Kadilli said that in December almost more than 100 million doses had been refused, "the majority due to product shelf life".

Gavi has ruled that doses must be valid for at least 10 weeks on arriving in countries.

- Patent gridlock -

Countries like South Africa and India have long called for the World Trade Organization to suspend intellectual property rights for vaccines and anti-Covid treatments, so they can massively boost production.

After fierce opposition from pharmaceutical giants, a first compromise was reached between the United States, European Union, India and South Africa last month.

But several key countries like Switzerland have yet to sign on. Doctors Without Borders also says there are "key limitations" in the deal, such as covering only vaccines and geographical limits.

Pharmaceutical companies argue that patents are not the real problem.

Cueni of IFPMA, a big pharma lobby group, said the problem was now logistics.

"What we need is money to have storage, transportation, more trained health workers, campaigns to counter misinformation: these are the real challenges and not the patent waiver," he said.

- New variants -

Current vaccines target the virus that swept the world in 2020. While they greatly reduce the risk of serious illness from Covid, they only provide partial protection -- particularly against newer variants such as the now dominant Omicron.

Several vaccine manufacturers have begun testing jabs that target Omicron. They have hit delays but could be available in a few months, if approved by health authorities.

And despite the billions yet to receive a first dose, the United States, Britain, France and Israel have started rolling out a fourth, starting with the most vulnerable.

On Wednesday, the EU's medicines watchdog approved a second booster for people aged 80 years and over.

"No country can boost its way out of the pandemic," Tedros has warned.

lem-ic-burs-dl/jm

I.Menon--DT